Skip to product information
1 of 3

Visby STI

Visby STI

Regular price $1,150.00 USD
Regular price Sale price $1,150.00 USD
Sale Sold out

The Visby Medical Sexual Health Test detects three of the most common and curable STIs: ChlamydiaGonorrheaTrichomoniasis — in under 30 minutes — so you can provide data-driven treatment in the same visit.

Click here for Our Medicaid Reimbursement Guide

*if first time purchase also order our power adapter.
Product Options
View full details

Test, talk and treat - in the same visit.

For self-collected vaginal swabs

  • Accurate
    Delivers ~97% accuracy. See our instructions for use.
  • Fast
    Results in under 30 minutes, while the patient is present.
  • CLIA-Waived
    Easy to use at the point-of-care; no extra instrument or maintenance needed.
  • Antibiotic stewardship
    Avoid unnecessary antibiotics.
Order Now

Visby Medical PCR

Game-changing: The first true PCR point-of-care device for STI that’s all-in-one and requires no separate instrument or reader. Results available during the patient’s visit help to eliminate the guesswork of empirical medicine and patient callbacks associated with lab send outs. With the confidence of a PCR result, clinicians can prescribe the correct treatment and engage in a clear, guiding discussion with the patient.

Three critical targets

Our sexual health test targets three pathogens that, if left untreated, can cause permanent damage to a woman’s reproductive system, including infertility, or potentially causing fatal ectopic pregnancy (pregnancy that occurs outside the womb). Fast PCR can help with early detection of these serious infections.

  • Chlamydia

    The most common reportable bacterial STI in the US2. Often without symptoms but is associated with significant healthcare costs, affects people of all ages, and is most common in young women.

    2. National overview – sexually transmitted disease surveillance, 2019. Centers for Disease Control and Prevention (CDC) website

  • Gonorrhea

    The second most common reportable condition in the US, this bacterial STI3, if untreated, may cause infertility. Babies of infected mothers can be infected during childbirth.

    3. National overview – sexually transmitted disease surveillance, 2019. Centers for Disease Control and Prevention (CDC) website

  • Trichomoniasis

    Caused by a protozoan parasite, Trichomoniasis is the third most common STI in the US4, yet most do not realize they are infected. Trichomoniasis increases the risk of contracting other STIs, including 2-3 times greater risk of HIV acquisition5.

    4. Microb Cell. 2016;3:404-418
    5. J Infect Dis. 2007;195:698-702

How to use the Visby Medical Sexual Health Test

Less than 15 seconds of hands-on time. Results in under 30 minutes.

Product Performance

Positive Percent Agreement (PPA) Negative Percent Agreement (NPA)
CT 97.4% 97.8%
NG 97.8% 99.1%
TV 99.3% 96.7%

Powerful and easy to use, anywhere

LED Status Lights

Indication lights inform testing operation status.

Sample collection port

An easy-to-slide switch secures the patient sample in the collection port.

Test control

A clear identifying spot that indicates test results are valid.

Quick, accurate results

With ~97% accuracy*, a spot next to the pathogen provides assurance that the patient sample is positive.

Downloads

Visby Medical developed PCR easy enough to be used by almost anyone, in any CLIA-waived setting. Below are resources to help run a successful test.

Instructions for Use

Specification Sheet

Distributer Guide

The power of PCR in your hands

Goodbye empirical treatment

Paper published in the Lancet

  • Visby Medical™ Sexual Health Test Results in More Appropriate Antibiotic Treatment

    05/30/2024 • Press Release

    Point-of-Care test significantly shortens time from ED arrival to test results, treatment and discharge – significant improvements are seen in the use of antibiotics for the treatment of chlamydia and gonococcal infections in women. Nationwide increases in sexually transmitted diseases and antibiotic resistance create the need for a paradigm shift from traditional lab-based molecular testing.

    Read full study